Trial Profile
A Phase 1 Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands in Patients With Acute Myeloid Leukemia (AML)/Advanced Myelodysplastic Syndrome (MDS-RAEB) and Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CYAD 01 (Primary)
- Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Celdara Medical; Celyad Oncology
- 30 May 2018 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Results of phase I portion of this study (n=11) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 07 Nov 2016 According to Celyad media release, results which will be presented during a poster session at the 58th American Society of Hematology (ASH) Annual Meeting.